UNIverse - Public Research Portal
Project cover

Cost-effectiveness of hyperkalemia treatment

Research Project
 | 
25.04.2016
 - 31.12.2019

An increase in blood-serum-potassium levels (hyperkalemia) is common in patients with renal impairment or heart failure. Indicated drug treatments, namely RAAS-inhibitors, (RAASi) such as ACE inhibitors, AT1 receptor-antagonists and aldosterone-blockers, lead to a further rise in potassium levels and may need to be discontinued despite their favourable cardiac and renal effects. Patiromer is an oral drug that can be used to treat latent/chronic hyperkalemia, reduce the risk of acute episodes of hyperkalemia, and enable the continuation of RAASi treatment. Based on clinical trial data, published literature and expert input, we have developed a decision-analytic model, composed of a decision-tree and a semi-Markov module, to evaluate the health economic properties of treatment with patiromer, for European countries.

Funding

Cost-effectiveness of hyperkalemia treatment

Industriegelder, Sonstige Forschungskooperationen (GrantsTool), 04.2016-06.2018 (27)
PI : Schwenkglenks, Matthias.
CI : Szucs, Thomas.

Members (4)

MALE avatar

Matthias Schwenkglenks

Principal Investigator
MALE avatar

Thomas Szucs

Co-Investigator
FEMALE avatar

Zanfina Ademi

Project Member
FEMALE avatar

Claudette Simone Sutherland

Project Member